The Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Acute Cholecystitis After a Routine Colonoscopy: A Case Report
- PMID: 40104488
- PMCID: PMC11919247
- DOI: 10.7759/cureus.79105
The Role of Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists in Acute Cholecystitis After a Routine Colonoscopy: A Case Report
Abstract
Colonoscopy (CLN) is a common procedure for colon cancer screening and diagnosing various conditions. Acute cholecystitis (AC), though rare, has been reported as a complication. We present a 66-year-old female on semaglutide for obesity who developed AC within 72 hours post-CLN. Considering the increasing use of glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and their impact on gallbladder motility, these medications may contribute to this complication. Future research is crucial to investigate whether a washout period for GLP-1 agonists before CLN is needed to reduce the risk of AC, if such a risk exists.
Keywords: acute cholecystitis; colonoscopy complications; glp-1 receptor agonist; pericholecystic fluid; semaglutide.
Copyright © 2025, Abdulraheem et al.
Conflict of interest statement
Human subjects: Consent for treatment and open access publication was obtained or waived by all participants in this study. Conflicts of interest: In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
Figures


Similar articles
-
New Avenues in the Regulation of Gallbladder Motility-Implications for the Use of Glucagon-Like Peptide-Derived Drugs.J Clin Endocrinol Metab. 2019 Jul 1;104(7):2463-2472. doi: 10.1210/jc.2018-01008. J Clin Endocrinol Metab. 2019. PMID: 30137354 Review.
-
GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art.Mol Metab. 2021 Apr;46:101102. doi: 10.1016/j.molmet.2020.101102. Epub 2020 Oct 14. Mol Metab. 2021. PMID: 33068776 Free PMC article. Review.
-
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: A replication study using reports to the World Health Organization pharmacovigilance database (VigiBase®).J Affect Disord. 2025 Jan 15;369:922-927. doi: 10.1016/j.jad.2024.10.062. Epub 2024 Oct 19. J Affect Disord. 2025. PMID: 39433133
-
Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system.Expert Opin Drug Saf. 2025 Apr 29:1-8. doi: 10.1080/14740338.2025.2499670. Online ahead of print. Expert Opin Drug Saf. 2025. PMID: 40285721
-
Challenges with glucagon-like peptide-1 (GLP-1) agonist initiation: a case series of semaglutide overdose administration errors.Clin Toxicol (Phila). 2024 Feb;62(2):131-133. doi: 10.1080/15563650.2024.2322049. Epub 2024 Mar 12. Clin Toxicol (Phila). 2024. PMID: 38470137
References
-
- Colonoscopy cholecystitis. Milman PJ, Goldenberg SP. Am J Gastroenterol. 2001;96:1666. - PubMed
Publication types
LinkOut - more resources
Full Text Sources